EMA Authorised: Biopoin (epoetin theta) — Teva GmbH

View source ↗

Summary

Biopoin (epoetin theta) has been authorised by the EMA for indications including chronic kidney failure, anemia, and cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Chronic Kidney Disease

Drugs mentioned

• Biopoin (epoetin theta)

Snippet

Status: Authorised. Therapeutic area: Kidney Failure, Chronic;Anemia;Cancer. MAH: Teva GmbH. Decision date: 26/09/2023